FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease

FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder) for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […]

Read More

FDA Approves Focused Ultrasound for Tremor-predominant Parkinson’s disease

FDA approves focused ultrasound for tremor-predominant Parkinson’s disease December 19, 2018 Tremor-predominant Parkinson’s disease (PD) joins Essential tremor (ET) as an FDA-approved indication for the use of Focused ultrasound. Focused ultrasound is a technology in which beams of ultrasound waves are focused on a designated target thereby concentrating enough energy to create a small lesion. […]

Read More

INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS® – Parkinson’s Disease Updates

INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS® – Parkinson’s Disease Updates

The International Congress of Parkinson’s Disease and Movement Disorders is taking place this week (Oct 5-9) in Hong Kong. This is an annual meeting of Movement Disorders scientists and physicians from around the world.

Read More

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other conditions

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other neuropsychiatric conditions

In classic biochemistry, ribonucleic acid (RNA) was thought to be a simple middle man between our genome and our proteins. Recently, however, it has become clear that RNA exists in multiple forms and plays a myriad of roles, including regulating protein production, regulating genome activity, and sensing environment. In fact, only a very small portion of DNA gets transcribed into RNA that creates protein. A much large portion gets transcribed into RNA that has various other functions.

Read More

FDA New Analysis on PD Psychosis Treatment

FDA New Analysis on PD Psychosis Treatment

On September 20, 2018, the FDA recently released results of a new analysis finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts

Read More